Cumberland Pharmaceuticals reports data from trial of ifetroban for DMD
US-based pharmaceutical company Cumberland Pharmaceuticals has reported positive top-line outcomes from a Phase II trial of ifetroban as a potential treatment for Duchenne muscular dystrophy (DMD).
A total of 41 subjects with DMD were enrolled in the double-blind, placebo-controlled FIGHT DMD trial, which lasted 12 months.
Subjects received either a daily dose of either 100mg (low dose) or 300mg (high dose) of the oral thromboxane receptor antagonist ifetroban or a placebo.
Improvement in the heart's left ventricular ejection fraction (LVEF) was the trial's primary endpoint.
The results showed that high-dose treatment of the therapy led to a 3.3% overall improvement in LVEF.
The high-dose arm experienced a 1.8% increase in LVEF, against a 1.5% decline in the placebo arm.
Compared with propensity-matched natural history controls, the high-dose treatment showed an overall improvement of 5.4%, as control subjects reported a decline of 3.6% in LVEF.
Both doses of the therapy were observed to be well-tolerated, without any serious drug-related events.
Ifetroban functions by blocking a receptor involved in inflammation and fibrosis, and has received orphan drug and rare paediatric disease statuses from the Food and Drug Administration (FDA).
If approved, the drug is expected to become the first therapy specifically indicated for DMD-related heart disease.
Cumberland Pharmaceuticals CEO AJ Kazimi said: 'As the first company to receive FDA orphan products development funding for a DMD clinical trial, we're honoured to be advancing a potential breakthrough therapy for DMD-related heart disease.
'These results validate our commitment to developing innovative treatments for rare diseases and underscore the importance of collaborative partnerships between industry, academia, and regulatory agencies in addressing critical unmet medical needs.'
Based in Tennessee, Cumberland Pharmaceuticals develops, acquires and commercialises products for hospital acute care, gastroenterology and oncology.
In May 2023, the company announced plans to launch the Phase II FIGHTING FIBROSIS trial of ifetroban for idiopathic pulmonary fibrosis (IPF).
"Cumberland Pharmaceuticals reports data from trial of ifetroban for DMD" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Xi Plays Long Game on US-China Trade as Trump Seeks Quick Wins
(Bloomberg) — While Donald Trump hailed the outcome of trade talks in London, Xi Jinping walked away with an understated strategic gain: a negotiating process that buys China time and helps defuse the threat of more harmful tariffs and technology curbs. Shuttered NY College Has Alumni Fighting Over Its Future Trump's Military Parade Has Washington Bracing for Tanks and Weaponry NYC Renters Brace for Price Hikes After Broker-Fee Ban NY Long Island Rail Service Resumes After Grand Central Fire Do World's Fairs Still Matter? Shortly after two days of negotiations wrapped, Trump declared Wednesday on social media that a deal had been 'DONE' to restore the flow of critical magnets from China, and pledged to lift curbs on student visas. Hours earlier, US Commerce Secretary Howard Lutnick revealed Washington would unwind its recent tech curbs, if niche metals essential to US auto and defense firms now flowed fast enough. China's focus was very different. A People's Daily commentary on Thursday — Beijing's most substantial comments so far on the talks — made no mention of export controls. Instead, the Communist Party mouthpiece touted an 'institutional guarantee' established in Geneva for the two sides to bridge differences via a 'consultation mechanism.' In a long-awaited leaders' call before the London negotiations, Xi told Trump the importance of using this channel, it added. The contrast illustrates a disconnect in how the world's biggest economies want to manage their trade dispute, and broader rollercoaster relationship. While Trump seeks quick deals done directly with top leaders, Xi favors a framework led by his lieutenants that wards against being blindsided. Such haggling could drag on for years, with the 'Phase One' deal from the first trade war taking most of Trump's first term. 'Xi is playing a longer game on US-China trade. His time in office is simply much longer than Trump's,' said Christopher Beddor, deputy China research director at Gavekal Research. 'That's not to say there's never any short-term thinking, but the lack of term limits presents very different incentives than for Trump.' While slow-walking negotiations allows China the chance to assess how hard a bargain Trump drives with other nations, the lingering uncertainty is bad for business, he added. Xi showed last week he can be flexible, getting on the phone with Trump as ties spiraled, breaking from the protocol to set up such an interaction. In the Biden era, then National Security Advisor Jake Sullivan and Foreign Minister Wang Yi would huddle in foreign locations for days before their leaders spoke directly, managing outcomes and expectations. While the Geneva talks last month wrapped with an identical US-China statement, suggesting a degree of alignment, that accord quickly fell apart over US claims China reneged on a promise to release shipments of rare earths. Beijing says it always intended to keep in place a permit process, which American companies complained moved so slowly some factories were forced to pause production. The lack of a detailed read out from either side this time around has left much in doubt, including on what Beijing committed to on the export of niche metals used in everything from fighter jets to electric vehicles. Lutnick told CNBC on Wednesday that China was going to approve 'all applications for magnets from the United States companies right away' — a sweeping claim that appeared to leave plenty of room for disappointment. Chinese Commerce Ministry spokesman He Yadong pledged his country would 'fully consider the reasonable needs and concerns of all countries in the civilian sector,' at a regular press briefing in Beijing on Thursday, adding that approval work was being strengthened. 'The Chinese incentive is also to keep cards close to their chest, and not make a lot of proclamations about what they have or have not committed to,' said Arthur Kroeber, founding partner and head of research at Gavekal. 'There is a lot of leeway for them within the whole export licensing regime.' One approach could be to restart enough export licenses so commercial buyers aren't stymied, but not so much that firms can stockpile, thus blunting Beijing's future leverage, he added. Adding to the fuzziness, Trump declared on social media that China now faces a 55% charge, a number that appears to include levies introduced during his first presidency. It also combines a 10% baseline duty imposed by Trump and a 20% tax tied to fentanyl trafficking — an area where Beijing was seen as having room to negotiate if it stepped up scrutiny of its companies. Lutnick cast doubt on that, and raised questions about the nature of future negotiations, saying that tariffs on China would 'definitely' stick at their current level. That suggests a 90-day pause set to expire in August on Trump's blanket 145% rate was now irrelevant. Such a position also dilutes the incentive for Beijing to offer concessions in future trade talks, if tariffs can't budge. While China has felt the pain from US levies, with exports to the world's largest economy plunging 34% in May, Trump appears to be in the bigger hurry to get a deal. His administration is facing a self-imposed July 9 deadline to either strike pacts with dozens of global trading partners or reimpose sweeping tariffs. In a sign of the Republican leader's growing impatience, he warned Wednesday that he will soon send letters to countries saying, 'this is the deal, you can take it or leave it.' Exemplifying that willingness to keep things moving, Trump's team in a rare move this week put export controls on the negotiating table — previously, such tools have been justified with national security concerns, and were largely off limits. Watering down that rationale could open the door to more cooperation, and advance Trump's stated goal to 'open up China to American trade.' Still, China is unlikely to agree to large purchases of goods that compete in areas where Beijing is looking to build self sufficiency and nurture its own national champions. Rebalancing their economies, a concept touted by US Treasury Secretary Scott Bessent, could involve attracting more Chinese investment into the US. Policy whiplash by the Trump administration might deter many Chinese companies from pouring money into the US economy, even if Xi were to encourage them to do so. Addressing these issues will take time, presumably requiring long discussions using the mechanism that China and US included in what Beijing called their 'hard won' agreement. 'Some people say that the result of the London talks was just a framework,' said Zhu Junwei, a former researcher in the People's Liberation Army who is now director of American research at Grandview Institution in Beijing. 'It's better to have a framework than have nothing.' —With assistance from Jing Li and Lucille Liu. American Mid: Hampton Inn's Good-Enough Formula for World Domination New Grads Join Worst Entry-Level Job Market in Years The Spying Scandal Rocking the World of HR Software US Tariffs Threaten to Derail Vietnam's Historic Industrial Boom The SEC Pinned Its Hack on a Few Hapless Day Traders. The Full Story Is Far More Troubling ©2025 Bloomberg L.P.
Yahoo
18 minutes ago
- Yahoo
Billionaire Blavatnik courted to take Daily Telegraph stake
The billionaire who has bankrolled DAZN, the sports-streaming service, is being courted to take a stake in The Daily Telegraph alongside the newspaper's new American majority-owners. Sky News has learnt that Sir Len Blavatnik, whose holding company Access Entertainment owns assets in Britain, including the Theatre Royal Haymarket, has been approached by RedBird Capital Partners about becoming a minority investor in the Telegraph titles. Two sources close to the situation said on Thursday that Sir Len was being sounded out about a deal, although they cautioned that no agreement had been struck and it remained unclear whether one would be. Sir Len, who was knighted by the late Queen Elizabeth II for services to philanthropy in 2017, is a prolific investor in the arts, media and entertainment industries. Access Entertainment is run by Danny Cohen, the former BBC director of television. Announcing its agreement to acquire Telegraph Media Group last month for an enterprise valuation of £500m, RedBird Capital said it was "in discussions with select UK-based minority investors with print media expertise and strong commitment to upholding the editorial values of the Telegraph". This was principally a reference to Lord Rothermere, the Daily Mail proprietor, who remains in talks to pay more than £30m for a stake in the Mail's rival right-leaning newspaper group. Goldman Sachs is advising DMGT on the investment, with a deal the subject of ongoing discussions, according to insiders. Read more: The Abu Dhabi state-backed vehicle IMI is still expected to acquire the maximum 15% stake in the Telegraph permitted under proposed new media ownership rules. The government's decision to set the ownership threshold at 15% follows an intensive lobbying campaign by newspaper industry executives concerned that a permanent outright ban could cut off a vital source of funding to an already-embattled industry. However, the deal faces continued opposition from parliamentarians, with The Guardian reporting on Thursday that a cross-party group had written to Lisa Nandy, the culture secretary, warning of "potential Chinese state influence" because of links between RedBird Capital chair John Thornton and China's sovereign wealth fund. This suggestion has been dismissed by RedBird Capital insiders. Ukraine-born Sir Len's portfolio of investments includes DAZN, which is now also backed by a Saudi sports group, mobile games studio Tripledot and Scenario Two, a theatre production company. Dovid Efune, the owner of The New York Sun, is meanwhile continuing to assemble a rival bid for the Telegraph, having secured backing from Jeremy Hosking, the prominent City investor. His prospects, however, look to have diminished after the former chancellor, Nadhim Zahawi, was reported to have withdrawn from his so-called 'British bid'. The Telegraph titles' parent company was forced into insolvency proceedings two years ago by Lloyds Banking Group, which ran out of patience with the Barclay family, their long-standing owner. RedBird IMI, a joint venture between the two firms, paid £600m several months later to acquire a call option that was intended to convert into ownership of the Telegraph newspapers and The Spectator magazine. That objective was thwarted by a change in media ownership laws, which banned any form of foreign state ownership. Some parliamentarians are continuing to argue that a 15% threshold would be too high, and that the proposed rules are ambiguous because they potentially allow for more than one state investor to aggregate their holdings in British newspapers. The Spectator was sold last year for £100m to Sir Paul Marshall, the hedge fund billionaire, who has installed Lord Gove, the former cabinet minister, as its editor. RedBird Capital has been contacted for comment, while a call to Access Industries' London office went unanswered on Thursday lunchtime.
Yahoo
21 minutes ago
- Yahoo
Nvidia (NVDA) to Host Virtual Annual Shareholder Meeting on June 25
Nvidia (NVDA, Financials) said Wednesday it will conduct its annual shareholder meeting virtually on June 25, with voting and live Q&A available via a secure online portal for registered stockholders. Warning! GuruFocus has detected 4 Warning Signs with NVDA. The Santa Clara-based semiconductor company, which has surged to a $3.49 trillion market valuation, said the proxy materials for the meeting were filed with the U.S. Securities and Exchange Commission on May 13. A recording of the session will remain accessible through June 2026. The meeting comes as Nvidia continues to expand its role in AI infrastructure globally. This month, the company unveiled plans to build an industrial AI cloud platform in Germany and named Micron Technology the first supplier for its new memory solution, SOCAMM, designed for AI server workloads. Nvidia also recently partnered with Novo Nordisk to use AI in drug discovery and showcased video compression tools for autonomous vehicles at its GTC conference in Paris. The company's Gefion supercomputer and GPU stack are being leveraged for breakthroughs across biotech, robotics, and high-performance computing. Nvidia stock closed down 0.75% on the day of the announcement. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
